Insilico Medicine researchers introduced LEGION, a hybrid artificial intelligence workflow combining mechanistic modeling with deep learning, designed to significantly expand chemical space exploration and simultaneously protect novel molecules from competitive patenting. Applied to the NLRP3 target implicated in inflammatory diseases and Parkinson’s, LEGION enables efficient molecule discovery optimized for novelty and therapeutic relevance. The platform aims to accelerate drug development while safeguarding intellectual property in a large chemical universe.